Cargando…
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer
The failure of current chemotherapeutic agents for pancreatic cancer (PCa) makes it the most aggressive soft tissue tumor with a 5-year survival of slightly above 10% and is estimated to be the second leading cause of cancer death by 2030. Objective: The main aim was to synthesize, characterize and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773620/ https://www.ncbi.nlm.nih.gov/pubmed/36550419 http://dx.doi.org/10.1186/s12885-022-10449-y |
_version_ | 1784855231723470848 |
---|---|
author | Ndemazie, Nkafu Bechem Inkoom, Andriana Ebesoh, Dexter Bulusu, Raviteja Frimpong, Esther Trevino, Jose Han, Bo Zhu, Xue Agyare, Edward |
author_facet | Ndemazie, Nkafu Bechem Inkoom, Andriana Ebesoh, Dexter Bulusu, Raviteja Frimpong, Esther Trevino, Jose Han, Bo Zhu, Xue Agyare, Edward |
author_sort | Ndemazie, Nkafu Bechem |
collection | PubMed |
description | The failure of current chemotherapeutic agents for pancreatic cancer (PCa) makes it the most aggressive soft tissue tumor with a 5-year survival of slightly above 10% and is estimated to be the second leading cause of cancer death by 2030. Objective: The main aim was to synthesize, characterize and evaluate the anticancer activity of 1,3-bistetrahydrofuran-2yl-5FU (MFU). Methods: MFU was synthesized by using 5-fluorouracil (5-FU) and tetrahydrofuran acetate, and characterized by nuclear magnetic resonance (NMR), micro-elemental analysis, high-performance liquid chromatography (HPLC), and liquid chromatography with mass spectrophotometry (LC-MS). MFU and Gemcitabine hydrochloride (GemHCl) were tested for antiproliferative activity against MiaPaca-2 and Panc-1 cell lines. Results: The half-minimum inhibitory concentration (IC(50)) of MFU was twice lower than that of GemHCl when used in both cell lines. MiaPaca-2 cells (MFU-IC(50) = 4.5 ± 1.2 μM vs. GemHCl-IC(50) = 10.3 ± 1.1 μM); meanwhile similar trend was observed in Panc-1 cells (MFU-IC(50) = 3.0 ± 1 μM vs. GemHCl-IC(50) = 6.1 ± 1.03 μM). The MFU and GemHCl effects on 3D spheroids showed a similar trend (IC(50-GemHCl) = 14.3 ± 1.1 μM vs. IC(50-MFU) = 7.2 ± 1.1 μM) for MiaPaca-2 cells, and (IC(50-GemHCl) = 16.3 ± 1.1 μM vs. IC(50-MFU) = 9.2 ± 1.1 μM) for Panc-1 cells. MFU significantly inhibited clonogenic cell growth, and induced cell death via apoptosis. Cell cycle data showed mean PI for GemHCl (48.5–55.7) twice higher than MFU (24.7 to 27.9) for MiaPaca-2 cells, and similarly to Panc-1 cells. The in-vivo model showed intensely stained EGFR (stained brown) in all control, GemHCl and MFU-treated mice bearing subcutaneous PDX tumors, however, HER2 expression was less stained in MFU-treated tumors compared to GemHCl-treated tumors and controls. Mean tumor volume of MFU-treated mice (361 ± 33.5 mm(3)) was three-fold lower than GemHCl-treated mice (1074 ± 181.2 mm(3)) bearing pancreatic PDX tumors. Conclusion: MFU was synthesized with high purity and may have potential anticancer activity against PCa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10449-y. |
format | Online Article Text |
id | pubmed-9773620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97736202022-12-23 Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer Ndemazie, Nkafu Bechem Inkoom, Andriana Ebesoh, Dexter Bulusu, Raviteja Frimpong, Esther Trevino, Jose Han, Bo Zhu, Xue Agyare, Edward BMC Cancer Research The failure of current chemotherapeutic agents for pancreatic cancer (PCa) makes it the most aggressive soft tissue tumor with a 5-year survival of slightly above 10% and is estimated to be the second leading cause of cancer death by 2030. Objective: The main aim was to synthesize, characterize and evaluate the anticancer activity of 1,3-bistetrahydrofuran-2yl-5FU (MFU). Methods: MFU was synthesized by using 5-fluorouracil (5-FU) and tetrahydrofuran acetate, and characterized by nuclear magnetic resonance (NMR), micro-elemental analysis, high-performance liquid chromatography (HPLC), and liquid chromatography with mass spectrophotometry (LC-MS). MFU and Gemcitabine hydrochloride (GemHCl) were tested for antiproliferative activity against MiaPaca-2 and Panc-1 cell lines. Results: The half-minimum inhibitory concentration (IC(50)) of MFU was twice lower than that of GemHCl when used in both cell lines. MiaPaca-2 cells (MFU-IC(50) = 4.5 ± 1.2 μM vs. GemHCl-IC(50) = 10.3 ± 1.1 μM); meanwhile similar trend was observed in Panc-1 cells (MFU-IC(50) = 3.0 ± 1 μM vs. GemHCl-IC(50) = 6.1 ± 1.03 μM). The MFU and GemHCl effects on 3D spheroids showed a similar trend (IC(50-GemHCl) = 14.3 ± 1.1 μM vs. IC(50-MFU) = 7.2 ± 1.1 μM) for MiaPaca-2 cells, and (IC(50-GemHCl) = 16.3 ± 1.1 μM vs. IC(50-MFU) = 9.2 ± 1.1 μM) for Panc-1 cells. MFU significantly inhibited clonogenic cell growth, and induced cell death via apoptosis. Cell cycle data showed mean PI for GemHCl (48.5–55.7) twice higher than MFU (24.7 to 27.9) for MiaPaca-2 cells, and similarly to Panc-1 cells. The in-vivo model showed intensely stained EGFR (stained brown) in all control, GemHCl and MFU-treated mice bearing subcutaneous PDX tumors, however, HER2 expression was less stained in MFU-treated tumors compared to GemHCl-treated tumors and controls. Mean tumor volume of MFU-treated mice (361 ± 33.5 mm(3)) was three-fold lower than GemHCl-treated mice (1074 ± 181.2 mm(3)) bearing pancreatic PDX tumors. Conclusion: MFU was synthesized with high purity and may have potential anticancer activity against PCa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10449-y. BioMed Central 2022-12-22 /pmc/articles/PMC9773620/ /pubmed/36550419 http://dx.doi.org/10.1186/s12885-022-10449-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ndemazie, Nkafu Bechem Inkoom, Andriana Ebesoh, Dexter Bulusu, Raviteja Frimpong, Esther Trevino, Jose Han, Bo Zhu, Xue Agyare, Edward Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title | Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title_full | Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title_fullStr | Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title_full_unstemmed | Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title_short | Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer |
title_sort | synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-fu as a potential agent for pancreatic cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773620/ https://www.ncbi.nlm.nih.gov/pubmed/36550419 http://dx.doi.org/10.1186/s12885-022-10449-y |
work_keys_str_mv | AT ndemazienkafubechem synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT inkoomandriana synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT ebesohdexter synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT bulusuraviteja synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT frimpongesther synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT trevinojose synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT hanbo synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT zhuxue synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer AT agyareedward synthesischaracterizationandanticancerevaluationof13bistetrahydrofuran2yl5fuasapotentialagentforpancreaticcancer |